Overview: P53 Immunohistochemistry TestIntroduction: The P53 Immunohistochemistry Test detects P53 protein to assess tumor suppressor gene mutations, aiding cancer prognosis. Following 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding prognosis, treatment planning, and improving outcomes in histopathology for patients with various cancers.
Other Names: P53 IHC Assay, Tumor Suppressor IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: P53 testing began in the 1980s with cancer research. Immunohistochemistry-based methods improved in the 2000s, enhancing prognostic precision.
Purpose: Detects P53 to assess tumor suppressor gene mutations, guides treatment, and evaluates cancer prognosis.
Test Parameters: 1. P53 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy or surgical resection. Report history of cancer diagnosis or symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document cancer history, tumor type, or symptoms (e.g., lumps, pain). Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, prognostic implications, and risks of biopsy or surgery.
Procedural Considerations: Uses immunohistochemistry to detect P53 in tumor tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for cancer prognosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive P53 staining suggests P53 mutations, indicating aggressive cancer and guiding intensive therapy. Negative staining suggests intact P53, potentially better prognosis.
Specialist Consultation: Consult an oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Tumor-specific IHC (e.g., HER-2, CK7), or next-generation sequencing to assess P53 mutations.
Test Limitations: P53 staining is not diagnostic on its own; clinical correlation is needed. Interpretation varies by tumor type.
References: WHO Tumor Classification Guidelines, 2023; American Journal of Surgical Pathology, Levine AJ, 2022.
